Displaying 841 - 860 of 1020 results
Promoting a Basic Understanding of Chemical Threats to Skin
https://www.niams.nih.gov/es/node/11066
Developing medical countermeasures to protect civilians against intentional and accidental toxic chemical exposure that can lead to mass casualties is a major goal of the biodefense program at NIH. More specifically, this goal is executed by the Chemical Countermeasures Research Program (CCRP) administered by NIAID and executed in partnership with several other ICs across the NIH, including NIAMS.
Weight loss and exercise to improve rheumatoid arthritis cardiovascular risk
https://www.niams.nih.gov/es/node/11141
Clinical Trials in the Spotlight Main Page The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal, and skin diseases. Investigators supported by the NIAMS need your help finding individuals to
Living With Scoliosis
https://www.niams.nih.gov/es/node/11146
An NIH Health Capsule article. Scoliosis is a disease that causes the spine to curve. It can result in an abnormal s-shaped or c-shaped curve. Anyone can get scoliosis. But it’s most common in children age 11 and older.
Division of Extramural Research
https://www.niams.nih.gov/es/node/11181
The Division of Extramural Research (DER) provides scientific management of the largest federal investment on arthritis, musculoskeletal, and skin diseases research conducted in academic institutions across the country. The DER consists of several distinct scientific and special programs, each headed by a program director. DER works with leadership at NIAMS
Drs. Heidi Kong and Ian Myles — Derm Germs: The Human Skin Microbiome
https://www.niams.nih.gov/es/node/10146
Dr. Heidi Kong uses genomics to uncover the microbe-host interactions taking place all over our skin.
Frequently Asked Questions for PAR-24-289 (R01) and PAR-25-230 (R21): Ancillary Studies to Ongoing Clinical Projects (Clinical Trial Not Allowed)
https://www.niams.nih.gov/es/node/10221
Applicants with additional questions are highly encouraged to contact their Program Director . These FAQs apply to the following funding opportunities: Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) (PAR-24-289) Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) (PAR-25-230)
Researchers Uncover Clues to Why Some Wounds Don’t Heal
https://www.niams.nih.gov/es/node/10281
Researchers identify defects in the wound healing process that might explain why diabetic foot ulcers heal slower or not at all.
NIH Researchers Discover a New Inflammatory Disease Called VEXAS
https://www.niams.nih.gov/es/node/10301
NIH scientists led an international team of researchers toward discovery of a new, adult-onset inflammatory disease abbreviated the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome.
The Stephen I. Katz Early Stage Investigator Research Grant Program
https://www.niams.nih.gov/es/node/10306
Dr. Stephen I. Katz directed the National Institute of Arthritis and Musculoskeletal and Skin Diseases from August 1995 until his death in December 2018. He is remembered as an outstanding scientist, administrator, and civil servant who was committed to excellence, transparency, integrity, and public trust. But perhaps most noteworthy were
Elif Eren, Ph.D.
https://www.niams.nih.gov/es/node/10311
Dr. Eren is a structural biochemist studying viral protein interactions with host proteins, nucleic acids, and antibodies using x-ray crystallography and cryo-EM. Her research focuses on novel drug targets and therapeutics for HIV-1, HBV, and SARS-CoV-2.
New NIH Research Grants Honor Legacy of Former NIAMS Director Stephen I. Katz, M.D., Ph.D.
https://www.niams.nih.gov/es/node/10326
We at NIAMS are excited as we look forward to the arrival of Lindsey Criswell as the new Director but our thoughts also turn back to memories of our previous Director, Steve Katz. He was a unique voice who guided the NIAMS as director for more than two decades and who spent his career mentoring the next generations of researchers. With this in mind, I am pleased to share news of new awards that give the NIH a unique way to encourage the scientists of tomorrow.
Frequently Asked Questions for Investigators Conducting NIAMS-Funded Clinical Research Studies
https://www.niams.nih.gov/es/node/10346
TABLE OF CONTENTS TERMINOLOGIES AND DEFINITIONS GENERAL DATA AND SAFETY MONITORING AND OVERSIGHT STUDY DOCUMENTS NIAMS CLINICAL FUNDING OPPORTUNITIES, REVIEW AND AWARD ANCILLARY STUDIES HUMAN SUBJECTS AND CLINICAL TRIALS INFORMATION FORM CLINICALTRIALS.GOV TRAINING REQUIREMENTS FOR CLINICAL TRIALS
Natalia Acevedo Luna, Ph.D.
https://www.niams.nih.gov/es/node/10406
Dr. Acevedo Luna is a postdoctoral fellow focusing on the mechanisms of non-coding RNAs acting in trans to regulate the expression of target genes and the modulation of chromatin 3D conformation during skeletal muscle specification and development.
From the Acting Director: Looking Ahead to a Brighter Year and Welcoming a New NIAMS Director
https://www.niams.nih.gov/es/node/10651
I think we can all agree that 2020 was a challenging year. The COVID-19 pandemic has affected all of us in unprecedented ways and has taken far too many lives. Despite that, I want to share some of my optimism for 2021.
Hong Jun Wang, Ph.D.
https://www.niams.nih.gov/es/node/10686
Dr. Wang is a biologist studying transcriptional regulation of skeletal muscle differentiation. Her research focuses on histone methyltransferase Ezh1 involved in skeletal muscle differentiation and metabolic regulation of epigenetics.